GLOBEALERT
BUSINESSLOW3h ago · Sep 10, 2026, 3:49 PM

Revolution a new overweight at Morgan Stanley on RAS-targeted oncology franchise

Seeking Alpha Tech · global

Morgan Stanley has given a new 'overweight' rating to Revolution based on its RAS-targeted oncology franchise. This indicates a positive outlook from the financial firm on the company's performance in cancer treatment development.

GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.

More in Business